Compare Citius Pharmaceuticals Inc (CTXR) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs LTC Properties Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while LTC Properties Inc trades at $42.42 (market cap $2.27B). The key difference: LTC Properties Inc is far larger — about 166.7× Citius Pharmaceuticals Inc's market cap, and LTC Properties Inc pays a 5.42% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and LTC Properties Inc for 89 Days on average.
| CTXR | LTC | |
|---|---|---|
Market Cap | $13.62M | $2.27B |
Volume | 132,438 | 574,171 |
Sector | Health | Real Estate |
52-Week High | $1.82 | $43.50 |
52-Week Low | $0.48 | $33.98 |
Typical Hold Time | 16 Days | 89 Days |
Enterprise Value | $3.79M | $3.01B |
Dividend Yield | — | 5.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
LTC Properties trades at $42.37, up 1.34% with a bullish technical signal. The REIT shows strong fundamentals with 2025 revenue of $262.85M and net income of $117.97M, delivering a 38.93% net margin. Recent acquisitions totaling $360M accelerate the SHOP portfolio transition, while consistent monthly dividends of $0.19 provide income stability. Analyst consensus sits at $49.67 with mixed ratings (7 Buy, 12 Hold, 3 Sell) amid strategic shifts.
Outlook remains positive due to demographic tailwinds in senior housing, though rising rates and execution risks on $730M asset sales pose challenges. Current valuation at P/E 15.02 appears reasonable for growth prospects, with technical support at $41-42 offering near-term stability. The stock presents a balanced opportunity for income and growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
